These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 23057994)

  • 1. Role of NT-proBNP in detection of myocardial damage in childhood leukemia survivors treated with and without anthracyclines.
    Mladosievicova B; Urbanova D; Radvanska E; Slavkovsky P; Simkova I
    J Exp Clin Cancer Res; 2012 Oct; 31(1):86. PubMed ID: 23057994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term cardiac effects of treatment for childhood leukemia.
    Urbanova D; Urban L; Simkova I; Danova K; Mikuskova E; Mladosievicova B
    Neoplasma; 2010; 57(2):179-83. PubMed ID: 20099983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study.
    Mavinkurve-Groothuis AM; Marcus KA; Pourier M; Loonen J; Feuth T; Hoogerbrugge PM; de Korte CL; Kapusta L
    Eur Heart J Cardiovasc Imaging; 2013 Jun; 14(6):562-9. PubMed ID: 23109647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiotoxicity of anthracycline (ANT) treatment in children with malignant tumors.
    Hu H; Zhang W; Huang D; Yang Q; Li J; Gao Y
    Pediatr Hematol Oncol; 2018 Mar; 35(2):111-120. PubMed ID: 29648903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines.
    Mavinkurve-Groothuis AM; Groot-Loonen J; Bellersen L; Pourier MS; Feuth T; Bökkerink JP; Hoogerbrugge PM; Kapusta L
    Pediatr Blood Cancer; 2009 May; 52(5):631-6. PubMed ID: 19127569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children.
    Sherief LM; Kamal AG; Khalek EA; Kamal NM; Soliman AA; Esh AM
    Hematology; 2012 May; 17(3):151-6. PubMed ID: 22664114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.
    Ekstein S; Nir A; Rein AJ; Perles Z; Bar-Oz B; Salpeter L; Algur N; Weintraub M
    J Pediatr Hematol Oncol; 2007 Jul; 29(7):440-4. PubMed ID: 17609620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NT-proBNP as early marker of subclinical late cardiotoxicity after doxorubicin therapy and mediastinal irradiation in childhood cancer survivors.
    Zidan A; Sherief LM; El-sheikh A; Saleh SH; Shahbah DA; Kamal NM; Sherbiny HS; Ahmad H
    Dis Markers; 2015; 2015():513219. PubMed ID: 25960594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines.
    Germanakis I; Kalmanti M; Parthenakis F; Nikitovic D; Stiakaki E; Patrianakos A; Vardas PE
    Int J Cardiol; 2006 Apr; 108(2):212-5. PubMed ID: 16290101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults.
    Dodos F; Halbsguth T; Erdmann E; Hoppe UC
    Clin Res Cardiol; 2008 May; 97(5):318-26. PubMed ID: 18193371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood.
    Vandecruys E; Mondelaers V; De Wolf D; Benoit Y; Suys B
    J Cancer Surviv; 2012 Mar; 6(1):95-101. PubMed ID: 21630046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myocardial 2D Strain During Long-Term (>5 Years) Follow-Up of Childhood Survivors of Acute Lymphoblastic Leukemia Treated With Anthracyclines.
    Pourier MS; Mavinkurve-Groothuis AMC; Dull MM; Weijers G; Loonen J; Bellersen L; de Korte CL; Kapusta L
    Am J Cardiol; 2020 Jul; 127():163-168. PubMed ID: 32444028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy.
    Lipshultz SE; Landy DC; Lopez-Mitnik G; Lipsitz SR; Hinkle AS; Constine LS; French CA; Rovitelli AM; Proukou C; Adams MJ; Miller TL
    J Clin Oncol; 2012 Apr; 30(10):1050-7. PubMed ID: 22393080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
    Horacek JM; Pudil R; Jebavy L; Tichy M; Zak P; Maly J
    Exp Oncol; 2007 Dec; 29(4):309-13. PubMed ID: 18199989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac biomarkers indicate a need for sensitive cardiac imaging among long-term childhood cancer survivors exposed to anthracyclines.
    Ylänen K; Poutanen T; Savukoski T; Eerola A; Vettenranta K
    Acta Paediatr; 2015 Mar; 104(3):313-9. PubMed ID: 25393922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of biomarkers and echocardiography in the evaluation of cardiotoxicity risk in children treated for leukemia.
    Raluca Maniu D; Blag C; Popa G; Bota M; Vlad C; Cainap C; Balacescu O; Pop L; Cainap SS
    J BUON; 2018 Dec; 23(7):122-131. PubMed ID: 30722121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late cardiac effects of anthracycline containing therapy for childhood acute lymphoblastic leukemia.
    Rathe M; Carlsen NL; Oxhøj H
    Pediatr Blood Cancer; 2007 Jun; 48(7):663-7. PubMed ID: 17405151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation.
    Roziakova L; Bojtarova E; Mistrik M; Dubrava J; Gergel J; Lenkova N; Mladosievicova B
    J Exp Clin Cancer Res; 2012 Feb; 31(1):13. PubMed ID: 22321767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved Cardiomyopathy Risk Prediction Using Global Longitudinal Strain and N-Terminal-Pro-B-Type Natriuretic Peptide in Survivors of Childhood Cancer Exposed to Cardiotoxic Therapy.
    Ehrhardt MJ; Liu Q; Mulrooney DA; Rhea IB; Dixon SB; Lucas JT; Sapkota Y; Shelton K; Ness KK; Srivastava DK; McDonald A; Robison LL; Hudson MM; Yasui Y; Armstrong GT
    J Clin Oncol; 2024 Apr; 42(11):1265-1277. PubMed ID: 38207238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical markers and assessment of cardiotoxicity during preparative regimen and hematopoietic cell transplantation in acute leukemia.
    Horacek JM; Pudil R; Tichy M; Jebavy L; Zak P; Slovacek L; Maly J
    Exp Oncol; 2007 Sep; 29(3):243-7. PubMed ID: 18004253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.